NCT02363283 2020-08-21Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaNational Cancer Institute (NCI)Phase 2 Completed37 enrolled 12 charts
NCT02302339 2019-09-06A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaCelldex TherapeuticsPhase 2 Terminated132 enrolled 16 charts